CFLD International (Indonesia), a new industrial city developer based in Singapore, received the presence of PT Brightgene Biomedical Indonesia at a groundbreaking event or the laying of a Brightgene factory building stone located in Karawang New Industry City (KNIC) on August 09, 2019

The plant, which is designed to be 25,000m2 with an investment of Rp. 580 billion for 10 years, will become Brightgene's production and R&D center for antiviral and anticancer drug products, as well as a formulation plant for cytotoxic and hormone products.

As an experienced industrial city developer, CFLD International provides integrated services, in the form of providing a waste management system, assistance in licensing from the establishment process to the company's operations, liaising with workers and the government and service providers.

Not only that, the CFLD will also ensure beneficial results for both parties by providing solutions from upstream to downstream that include research and planning, factory site selection, platform construction, support for industry, services, and operations.

The groundbreaking event of the factory and R&D center of PT Brightgene Biomedical Indonesia at KNIC was also witnessed by the Indonesian Minister of Health, Prof. Dr. dr. Nila Djuwita F. Moeloek, Sp.M (K), Deputy for Drug and Drug Control of BPOM, Dra. Rita Endang, Apt., M. Kes., Indonesian Ambassador to China, Djauhari Oratmangun, Karawang District Government, as well as company leaders.

Bringing 20 years of experience in the biomedical world from Suzhou China, Brightgene established PT Brightgene Biomedical Indonesia along with experienced Indonesian pharmaceutical professionals to be able to produce medicines locally.

Thus, Brightgene can produce drugs at competitive prices which in the future are expected to have an impact on the reduction in the national budget for the cost of procurement of medicines so that they are more affordable for patients in Indonesia.